
|Articles|January 6, 2010
Novartis announces option exercise and merger proposal
Novartis is to exercise its option to purchase the remaining shares in Alcon, Inc., owned by Nestle S.A. at a weighted average price of US$180 per share in cash following the agreement between Nestle and Novartis in April 2008.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Lumvoa gains US FDA approval for thyroid eye disease with class-first broad label
2
European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease
3
DEX implant shows benefit across RVO subgroups in real-world retrospective study
4

























